Dicycloverine

BRAND NAMES

1. Bentyl – widely used for irritable bowel syndrome and intestinal spasms. 

2. Dicyclomine – another commonly prescribed brand for gastrointestinal spasm relief.

MECHANISM OF ACTION

Dicycloverine is an anticholinergic (antimuscarinic) agent that works by inhibiting the action of acetylcholine on smooth muscle receptors in the gastrointestinal tract. By blocking muscarinic receptors, it reduces spasmodic contractions of the gut, decreases intestinal motility, and alleviates abdominal cramping and pain associated with conditions like irritable bowel syndrome (IBS). Additionally, it has a mild direct smooth muscle relaxant effect, enhancing its ability to relieve visceral discomfort.

PHARMACOKINETICS

Absorption

Dicycloverine is well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically achieved within 1–2 hours after ingestion of tablets or capsules. The drug’s absorption may be influenced slightly by food intake, which can delay the time to peak concentration but does not significantly reduce overall bioavailability.

Distribution

Dicycloverine has a moderate volume of distribution, reflecting its distribution primarily to gastrointestinal smooth muscle and other tissues. It is widely distributed in body tissues after oral absorption but shows limited penetration into the central nervous system at therapeutic doses.

Metabolism

Dicycloverine undergoes extensive hepatic metabolism after oral absorption. It is primarily metabolized by liver enzymes, producing metabolites that are largely inactive. The metabolism contributes to its relatively short half-life and the need for multiple daily doses to maintain therapeutic effect.

Elimination

Dicycloverine is eliminated primarily via renal excretion, with both unchanged drug and metabolites appearing in the urine. A smaller portion is excreted in feces. Its elimination half-life ranges from approximately 1.5 to 2 hours, necessitating multiple daily dosing to maintain effective plasma levels.

PHARMACODYNAMICS

Dicycloverine exerts its pharmacodynamic effects by blocking muscarinic receptors on gastrointestinal smooth muscle, which reduces spasmodic contractions and intestinal motility. This action alleviates abdominal cramping, pain, and discomfort associated with conditions such as irritable bowel syndrome (IBS). Its direct smooth muscle relaxant effect further contributes to the relief of visceral tension.

ADMINISTRATION

Dicycloverine is typically administered orally in the form of tablets, capsules, or syrup. For adults and children above a specified age, it is usually taken 30–60 minutes before meals to optimize its antispasmodic effect during periods of gastrointestinal activity. The medication should be swallowed whole with water and not chewed or crushed, unless a specific formulation allows it.

DOSAGE AND STRENGTH

Dicycloverine is available in oral tablet, capsule, and syrup formulations. The typical adult dosage is 10–20 mg taken 3–4 times daily, 30–60 minutes before meals, depending on symptom severity. Pediatric dosing is usually based on body weight, often 0.2–0.3 mg/kg per dose, given 3–4 times daily. The drug is formulated to provide rapid gastrointestinal absorption while minimizing systemic side effects.

DRUG INTERACTIONS

Dicycloverine, an anticholinergic agent used to treat irritable bowel syndrome, can interact with several types of medications due to its effects on smooth muscle and the nervous system. Concomitant use with other anticholinergic drugs, such as atropine, scopolamine, antihistamines, or tricyclic antidepressants, can lead to additive anticholinergic effects, including dry mouth, constipation, urinary retention, blurred vision, and confusion.

FOOD INTERACTIONS

Dicycloverine has no significant food interactions, and it can be taken with or without meals. However, alcohol should be avoided or limited, as it can enhance the drug’s sedative effects, leading to dizziness, drowsiness, or impaired coordination. While caffeine and spicy foods do not directly interfere with dicycloverine, they may exacerbate gastrointestinal symptoms that the medication is intended to relieve.

CONTRAINDICATIONS

Dicycloverine is contraindicated in patients with conditions where its anticholinergic effects could cause harm. These include narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis or gastrointestinal obstruction, and toxic megacolon. It should not be used in individuals with urinary retention or intestinal atony.

SIDE EFFECTS

• Dry mouth 

• Blurred vision 

• Constipation 

• Nausea or mild stomach upset

• Dizziness or drowsiness 

• Lightheadedness

OVER DOSAGE

Overdose of dicycloverine can be serious and potentially life-threatening due to its anticholinergic effects. Symptoms may include severe dry mouth, blurred vision, dilated pupils, rapid heartbeat, flushing, constipation, urinary retention, dizziness, confusion, agitation, hallucinations, and in extreme cases, seizures or respiratory depression. Immediate medical attention is essential.

TOXICITY

Dicycloverine toxicity results from overdose or drug accumulation and is primarily due to its anticholinergic effects. Symptoms can include severe dry mouth, blurred vision, sensitivity to light, marked constipation, urinary retention, rapid or irregular heartbeat, flushing, fever, and neurological disturbances such as confusion, agitation, hallucinations, delirium, and in severe cases, seizures or respiratory depression. Management requires immediate medical attention, with supportive care focused on monitoring vital signs, maintaining hydration and airway, and treating complications.